INOSR APPLIED SCIENCES 12(3):1-5, 2024 ISSN: 2705-165X
©INOSR PUBLICATIONS INOSR12.3.15.000
International Network Organization for Scientific Research
https://doi.org/10.59298/INOSRAS/2024/12.3.15000

Resistance to Antimalarial Drugs in Uganda: Current Status and Future Directions

Irakoze Mukamana S.

School of Applied Health Sciences Kampala International University Uganda

ABSTRACT

Antimalarial drug resistance posed a significant challenge to malaria control in Uganda, where Plasmodium falciparum remains the predominant strain. This review examined the current status of antimalarial drug resistance in Uganda, focusing on the mechanisms underlying resistance, epidemiological trends, and the impact on malaria control programs. Chloroquine and sulfadoxine-pyrimethamine resistance have been well-documented, and recent concerns about reduced efficacy of artemisinin-based combination therapies (ACTs) highlight ongoing challenges. The review identified key mechanisms of resistance, including genetic mutations, drug efflux, metabolic pathway alterations, and potential biofilm formation. The implications of resistance on treatment efficacy, healthcare costs, and policy adjustments are discussed. Future directions included strengthening surveillance systems, optimizing combination therapies, investing in research and development, implementing integrated vector management strategies, and enhancing public education and community engagement. Related published literatures were reviewed and analysis of recent data on drug resistance patterns in Uganda was carried out and utilised in compiling this paper. By exploring these dimensions, the review aims to provide actionable insights for policymakers, healthcare providers, and researchers to effectively address drug resistance and advance malaria control efforts in Uganda.

Keywords: Antimalarial Drug Resistance, Plasmodium falciparum, Chloroquine Resistance, Artemisinin-Based Combination Therapies (ACTs), Surveillance and Monitoring.

INTRODUCTION

Malaria continues to be a major public health challenge in Uganda, with Plasmodium falciparum accounting for the majority of cases[1–3]. Despite significant efforts to control and reduce the burden of malaria, the emergence and spread of resistance to antimalarial drugs threaten the progress made over the past decades. Antimalarial drug resistance, particularly to widely used treatments such as chloroquine, sulfadoxine-pyrimethamine, and artemisinin-based combination therapies (ACTs), has complicated treatment protocols and increased the difficulty of managing malaria effectively[4, 5]. Chloroquine resistance first emerged in the 1980s, prompting a shift to alternative treatments such as sulfadoxine-pyrimethamine, which also eventually encountered resistance[6, 7]. The adoption of ACTs brought hope for better control, but recent reports of reduced efficacy and delayed parasite clearance raise concerns about the potential for widespread resistance to these frontline therapies as well[8, 9].

This ongoing battle against drug-resistant malaria in Uganda is compounded by various factors, including genetic mutations in the parasite, socioeconomic challenges, limited healthcare infrastructure, and environmental conditions favorable to mosquito breeding[10]. The implications of antimalarial drug resistance are profound, leading to higher morbidity and mortality rates, increased healthcare costs, and the necessity for frequent updates to treatment policies. Addressing this issue requires a comprehensive understanding of the current resistance patterns, robust surveillance systems, effective drug policies, and continuous research into new treatment options[11–13]. Additionally, integrating vector control measures, promoting community engagement, and ensuring political commitment are essential strategies for managing and eventually overcoming drug-resistant malaria. This review aims to provide an in-depth analysis of the current

status of antimalarial drug resistance in Uganda, exploring the mechanisms behind resistance, the epidemiological trends, and the impact on public health. It also discusses future directions and potential solutions to mitigate the challenges posed by drug resistance, with a focus on sustainable and effective malaria control strategies[14, 15]. By examining the successes and obstacles faced in combating antimalarial drug resistance, this review seeks to inform policy-makers, healthcare providers, and researchers on the best practices and innovative approaches needed to address this critical issue.

MECHANISMS OF ANTIMALARIAL DRUG RESISTANCE

Antimalarial drug resistance occurs when parasites develop the ability to survive and multiply despite the presence of therapeutic concentrations of drugs. Specific genetic mutations in the parasite can confer resistance to antimalarial drugs. For example, mutations in the PfCRT gene are associated with chloroquine resistance, while mutations in the dhfr and dhps genes are linked to resistance to sulfadoxine-pyrimethamine [16]. Parasites may develop mechanisms to pump drugs out of their cells, reducing the effective concentration of the drug within the parasite. This is often mediated by transporter proteins such as PfMDR1. Changes in the metabolic pathways of the parasite can also contribute to drug resistance. For example, alterations in the folate pathway can lead to resistance to antifolate drugs[17, 18]. Although more relevant in bacterial resistance, some studies suggest that biofilm-like structures in malaria parasites could play a role in protecting them from drug action.

EPIDEMIOLOGICAL TRENDS OF ANTIMALARIAL DRUG RESISTANCE IN UGANDA

The epidemiology of antimalarial drug resistance in Uganda has evolved over the past few decades. Chloroquine was once the mainstay of malaria treatment in Uganda. However, widespread resistance led to its replacement with sulfadoxine-pyrimethamine in the late 1990s. Resistance to sulfadoxine-pyrimethamine emerged rapidly, prompting a further shift to ACTs in the early 2000s. Despite this, sulfadoxine-pyrimethamine is still used for intermittent preventive treatment in pregnant women (IPTp). ACTs, particularly artemether-lumefantrine, are the current first-line treatment for malaria in Uganda[19–21]. However, there are growing concerns about reduced efficacy and delayed parasite clearance times, particularly in regions with high transmission rates. The prevalence and intensity of drug resistance can vary significantly across different regions of Uganda, influenced by factors such as drug usage patterns, transmission intensity, and healthcare access.

IMPACT ON MALARIA CONTROL PROGRAMS

The emergence of drug-resistant malaria has several implications for malaria control programs in Uganda[22, 23]:

Treatment Failures: Resistance leads to increased treatment failures, resulting in prolonged illness, higher transmission rates, and increased mortality.

Increased Healthcare Costs: Managing drug-resistant malaria is more expensive due to the need for more complex and costly treatment regimens, increased diagnostic testing, and longer hospital stays.

Policy Adjustments: Resistance necessitates frequent updates to treatment guidelines and policies, which can be challenging to implement consistently across the country.

Community Trust: Repeated treatment failures can undermine community trust in healthcare systems and malaria control efforts, reducing adherence to prescribed treatments and preventive measures.

Future Directions

Addressing antimalarial drug resistance in Uganda requires a multifaceted approach:

i. **Surveillance and Monitoring:** Strengthening surveillance systems to detect and monitor drug resistance is critical. This includes regular therapeutic efficacy studies and molecular surveillance to track genetic markers of resistance.

ii. **Combination Therapies:** Using multiple drugs with different mechanisms of action can help delay the development of resistance. Research into new combination therapies and optimizing existing ones is essential.

iii. **Research and Development:** Investing in the development of new antimalarial drugs, vaccines, and diagnostic tools is crucial. Partnerships between governments, academia, and the private sector can accelerate this process.

iv. **Integrated Vector Management (IVM):** Reducing malaria transmission through vector control measures can decrease the reliance on drugs and slow the spread of resistance. IVM strategies include the use of insecticide-treated nets, indoor residual spraying, and environmental management.

v. **Public Education and Community Engagement:** Educating communities

about the importance of adhering to treatment regimens and preventive measures can enhance the effectiveness of malaria control programs. Engaging community leaders and influencers can help promote behavior change.

vi. **Policy and Funding:** Ensuring adequate funding and political commitment to malaria control efforts is essential. Policies should support research, surveillance, and the implementation of effective interventions.

CONCLUSION

Antimalarial drug resistance poses a significant challenge to malaria control efforts in Uganda. Addressing this issue requires a comprehensive approach that includes robust surveillance, innovative treatment strategies, and community engagement. By investing in research and development, strengthening healthcare systems, and fostering international collaborations, Uganda can make significant strides in mitigating the impact of drug resistance and moving towards the ultimate goal of malaria elimination.

REFERENCES

1. Allen, E.N., Wiyeh, A.B., McCaul, M.: Adding rapid diagnostic tests to community-based programmes for treating malaria. Cochrane Database Syst Rev. 2022, CD009527 (2022). https://doi.org/10.1002/14651858.CD009527.pub3
2. Alum, E., Ugwu, P.-C., Egba, S., Uti, D., Alum, B., Extension, K.P.: Climate Variability and Malaria Transmission: Unraveling the Complex Relationship. INOSR Scientific Research. 11, 16–22 (2024). https://doi.org/10.59298/INOSRSR/2024/1.1.21622
3. Erisa, K., Raphael, I., P.C., U., Alum, E.: Exploration of Medicinal Plants Used in the Management of Malaria in Uganda. (2023)
4. Egwu, C.O., Aloke, C., Chukwu, J., Agwu, A., Alum, E., Tsamesidis, I., Aja, P.M., Offor, C.E., Obasi, N.A.: A world free of malaria: It is time for Africa to actively champion and take leadership of elimination and eradication strategies. Afr Health Sci. 22, 627–640 (2022). https://doi.org/10.4314/ahs.v22i4.68
5. Egwu, C.O., Aloke, C., Chukwu, J., Nwankwo, J.C., Irem, C., Nwagu, K.E., Nwite, F., Agwu, A.O., Alum, E., Offor, C.E., Obasi, N.A.: Assessment of the Antimalarial Treatment Failure in Ebonyi State, Southeast Nigeria. Journal of Xenobiotics. 13, 16–26 (2023). https://doi.org/10.3390/jox13010003
6. Anangwe Amimo, F.: Malaria Transmission Dynamics in East Africa. In: Eva Amoah, L., Kojo Acquah, F., and Kumi Asare, K. (eds.) Infectious Diseases. IntechOpen (2024)
7. Bauserman, M., Conroy, A.L., North, K., Patterson, J., Bose, C., Meshnick, S.: An overview of malaria in pregnancy. Seminars in Perinatology. 43, 282–290 (2019). https://doi.org/10.1053/j.semperi.2019.03.018
8. Kokori, E., Olatunji, G., Akinboade, A., Akinoso, A., Egbunu, E., Aremu, S.A., Okafor, C.E., Oluwole, O., Aderinto, N.: Triple artemisinin-based combination therapy (TACT): advancing malaria control and eradication efforts. Malaria Journal. 23, 25 (2024). https://doi.org/10.1186/s12936-024-04844-y
9. Obeagu, E.I., Alum, E.U., Ugwu, O.P.C. Hepcidin: The Gatekeeper of Iron in Malaria Resistance. NIJRMS. 4, 1–8 (2023). https://doi.org/10.59298/NIJRMS/2023/10.1.1400
10. Rosenthal, P., Asua, V., Conrad, M.: Emergence, transmission dynamics and mechanisms of artemisinin partial resistance in malaria parasites in Africa. Nature Reviews Microbiology. 22, (2024). https://doi.org/10.1038/s41579-024-01008-2
11. Ippolito, M.M., Moser, K.A., Kabuya, J.-B.B., Cunningham, C., Juliano, J.J.: Antimalarial Drug Resistance and Implications for the WHO Global Technical Strategy. Curr Epidemiol Rep. 8, 46–62 (2021). https://doi.org/10.1007/s40471-021-00266-5
12. Rasmussen, C., Alonso, P., Ringwald, P.: Current and emerging strategies to combat antimalarial resistance. Expert Review of Anti-infective Therapy. 20, 353–372 (2022). https://doi.org/10.1080/14787210.2021.1962291
13. Ansah, E.K., Moucheraud, C., Arogundade, L., Rangel, G.W.: Rethinking integrated service delivery for malaria. PLOS Global Public Health. 2, e0000462 (2022). https://doi.org/10.1371/journal.pgph.0000462
14. Liang, D., Jin, J.-J., Wang, W.-M., Cao, Y.-Y., Zhu, G.-D., Zhou, H.-Y., Cao, J., Huang, J.-Y.: Evaluating the implementation of rapid diagnostic tests in a malaria elimination setting. Infectious Diseases of Poverty. 9, (2020). https://doi.org/10.1186/s40249-020-00702-6

15. Mbonye, A.K., Buregyeya, E., Rutebemberwa, E., Clarke, S.E., Lal, S., Hansen, K.S., Magnussen, P., LaRussa, P.: Treatment and prevention of malaria in pregnancy in the private health sector in Uganda: implications for patient safety. Malaria Journal. 15, 212 (2016). https://doi.org/10.1186/s12936-016-1245-2
16. Hodoameda, P.: P. falciparum and Its Molecular Markers of Resistance to Antimalarial Drugs. Plasmodium Species and Drug Resistance [Working Title]. (2021)
17. Cowell, A., Winzeler, E.: The genomic architecture of antimalarial drug resistance. Briefings in Functional Genomics. (2019)
18. Kekani, L.N., Witika, B.A.: Current advances in nanodrug delivery systems for malaria prevention and treatment. Discover Nano. 18, 66 (2023). https://doi.org/10.1186/s11671-023-03849-x
19. Jiang, T., Chen, X.-S.: Outcome Impacts Due to Pathogen-Specific Antimicrobial Resistance: A Narrative Review of Published Literature. International Journal of Environmental Research and Public Health. 17,1395(2020). https://doi.org/10.3390/ijerph17041395
20. Mbogo, G.W., Nankoberanyi, S., Tukwasibwe, S., Baliraine, F.N., Nsobya, S., Conrad, M.D., Arinaitwe, E., Kamya, M., Tappero, J., Staedke, S., Dorsey, G., Greenhouse, B., Rosenthal, P.: Temporal changes in prevalence of molecular markers mediating antimalarial drug resistance in a high malaria transmission setting in Uganda. American Journal of Tropical Medicine and Hygiene. (2014)
21. Asua, V.: PA-285 Plasmodium falciparum antimalarial drug resistance: population-based spatio-temporal evolutionary trends in Uganda. Abstracts of Poster and e-Poster Presentations. A59.1-A59 (2023). https://doi.org/10.1136/bmjgh-2023-EDC.144
22. Conrad, M.D., Asua, V., Garg, S., Giesbrecht, D., Niaré, K., Smith, S., Namuganga, J.F., Katairo, T., Legac, J., Crudale, R.M., Tumwebaze, P.K., Nsobya, S.L., Cooper, R.A., Kamya, M.R., Dorsey, G., Bailey, J.A., Rosenthal, P.J.: Evolution of Partial Resistance to Artemisinins in Malaria Parasites in Uganda. N Engl J Med. 389, 722–732(2023). https://doi.org/10.1056/NEJMoa2211803
23. Nankabirwa, J.I., Rek, J., Arinaitwe, E., Namuganga, J.F., Nsobya, S.L., Asua, V., Mawejje, H.D., Epstein, A., Greenhouse, B., Rodriguez-Barraquer, I., Briggs, J., Krezanoski, P.J., Rosenthal, P.J., Conrad, M., Smith, D., Staedke, S.G., Drakeley, C., Bousema, T., Andolina, C., Donnelly, M.J., Kamya, M.R., Dorsey, G.: East Africa International Center of Excellence for Malaria Research: Summary of Key Research Findings. Am J Trop Med Hyg. 107, 21–32 (2022). https://doi.org/10.4269/ajtmh.21-1285

CITE AS: Irakoze Mukamana S. (2024). Resistance to Antimalarial Drugs in Uganda: Current Status and Future Directions. INOSR APPLIED SCIENCES 12(3):1-5.
https://doi.org/10.59298/INOSRAS/2024/12.3.15000